The FDA has finalized guidance on using electronic health record (EHR) data in clinical trials.
With a nationwide push toward incorporating real-world evidence in decision making, the FDA has finalized guidance on using electronic health record (EHR) data in clinical trials.
The guidance is intended to assist sponsors, clinical investigators, and other stakeholders in using the data for clinical investigations.
“In an effort to modernize and streamline clinical investigations, the goals of the guidance are to facilitate the use of EHR data in clinical investigations and to promote the interoperability of EHR and electronic data capture (EDC) systems,” stated the document.
The final guidance comes 2 years after the FDA announced the availability of the draft guidance. The guidance provides recommendations and best practices for:
Based on feedback during the comment period, the final guidance includes clarifications for:
Access to real-world data has the potential to support the approval of new indications for already approved drugs, as well as other regulatory decisions based on clinical investigations. During the 2018 American Society of Clinical Oncology Annual Meeting, June 1-5, in Chicago, Illinois, a session discussed the growing role of real-world evidence and how it can be leveraged in combination with clinical trials to inform evidence-based care.
Panelists highlighted some gaps in clinical trials that real-world evidence can fill. They noted that trials are not the optimal fit for questions of application of the innovation to broad and diverse populations and they are not well suited to answer post-hoc questions about differences in efficacy among subgroups or application to populations outside the clinical trials, often due to a small and/or homogenous sample size.
Real-world evidence can address those gaps by providing robust and well-rounded data, they argued.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More